Skip Nav Destination
Issues
15 December 2023
-
Cover Image
Cover Image
The cover shows a section of a bone marrow biopsy from a patient with multiple myeloma treated with pelareorep, bortezomib, and dexamethasone. Imaging mass cytometry shows histone H3 in blue, CD138 in red, and cleaved caspase 3 in green. For details, see the article by Nawrocki and colleagues on page 5087 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Drug Updates
FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Jennifer J. Gao; Christy L. Osgood; Zhou Feng; Erik W. Bloomquist; Shenghui Tang; C.J. George Chang; Tiffany K. Ricks; Sherry C. Hou; William F. Pierce; Donna R. Rivera; Richard Pazdur; Paul G. Kluetz; Laleh Amiri-Kordestani
Review
Clinical Trials: Targeted Therapy
Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer
Elena Shagisultanova; William Gradishar; Ursa Brown-Glaberman; Pavani Chalasani; Andrew J. Brenner; Alison Stopeck; Hannah Parris; Dexiang Gao; Tessa McSpadden; Jose Mayordomo; Jennifer R. Diamond; Peter Kabos; Virginia F. Borges
A Pilot Study Omitting Radiation in the Treatment of Children with Newly Diagnosed Wnt-Activated Medulloblastoma
Kenneth J. Cohen; Vasu Munjapara; Dolly Aguilera; Robert C. Castellino; Stacie L. Stapleton; Daniel Landi; David M. Ashley; Fausto J. Rodriguez; Cynthia Hawkins; Edward Yang; Wendy London; Susan Chi; Pratiti Bandopadhayay
Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
Missak Haigentz, Jr; Jeannette Y. Lee; Elizabeth Y. Chiao; David M. Aboulafia; Lee Ratner; Richard F. Ambinder; Robert A. Baiocchi; Ronald T. Mitsuyasu; William Wachsman; Joseph A. Sparano; Michelle A. Rudek
A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
Brandon M. Huffman; Hanrong Feng; Kalindi Parmar; Junning Wang; Kevin S. Kapner; Bose Kochupurakkal; David B. Martignetti; Golbahar Sadatrezaei; Thomas A. Abrams; Leah H. Biller; Marios Giannakis; Kimmie Ng; Anuj K. Patel; Kimberly J. Perez; Harshabad Singh; Douglas A. Rubinson; Benjamin L. Schlechter; Elizabeth Andrews; Alison M. Hannigan; Stanley Dunwell; Zoe Getchell; Srivatsan Raghavan; Brian M. Wolpin; Caroline Fortier; Alan D. D'Andrea; Andrew J. Aguirre; Geoffrey I. Shapiro; James M. Cleary
Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 Trial
Raphael Koch; Lianne Haveman; Ruth Ladenstein; Benedicte Brichard; Heribert Jürgens; Sona Cyprova; Henk van den Berg; Wolf Hassenpflug; Anna Raciborska; Torben Ek; Daniel Baumhoer; Gerlinde Egerer; Leo Kager; Marleen Renard; Peter Hauser; Stefan Burdach; Judith V.M.G. Bovee; Angela M. Hong; Peter Reichardt; Jarmila Kruseova; Arne Streitbürger; Thomas Kühne; Torsten Kessler; Marie Bernkopf; Trude Butterfaß-Bahloul; Catharina Dhooge; Sebastian Bauer; János Kiss; Michael Paulussen; Fiona Bonar; Andreas Ranft; Beate Timmermann; Jelena Rascon; Volker Vieth; Jukka Kanerva; Andreas Faldum; Wolfgang Hartmann; Lars Hjorth; Vivek A. Bhadri; Markus Metzler; Hans Gelderblom; Uta Dirksen
Clinical Trials: Immunotherapy
Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial
Akira Kawai; Mikiya Ishihara; Tomoki Nakamura; Shigehisa Kitano; Shintaro Iwata; Kohichi Takada; Makoto Emori; Koji Kato; Makoto Endo; Yoshihiro Matsumoto; Shigeki Kakunaga; Eiichi Sato; Yoshihiro Miyahara; Kunihiko Morino; Shinya Tanaka; Shuichi Takahashi; Fujio Matsuo; Akihiko Matsumine; Shinichi Kageyama; Takafumi Ueda
Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
Hitomi S. Okuma; Keisuke Watanabe; Kenji Tsuchihashi; Ryunosuke Machida; Ryo Sadachi; Akihiro Hirakawa; Hiroshi Ariyama; Masashi Kanai; Masahisa Kamikura; Kenta Anjo; Akari Hiramitsu; Shigeki Sekine; Natsuko Okita; Hiroyuki Mano; Hiroyoshi Nishikawa; Kenichi Nakamura; Kan Yonemori
Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial
Steffan T. Nawrocki; Julian Olea; Claudia Villa Celi; Homa Dadrastoussi; Kaijin Wu; Denice Tsao-Wei; Anthony Colombo; Matt Coffey; Eduardo Fernandez Hernandez; Xuelian Chen; Gerard J. Nuovo; Jennifer S. Carew; Ann F. Mohrbacher; Paul Fields; Peter Kuhn; Imran Siddiqi; Akil Merchant; Kevin R. Kelly
Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC)
MinKe He; YeXing Huang; ZeFeng Du; ZhiCheng Lai; Hanyue Ouyang; JingXian Shen; DongSheng Wen; QiJiong Li; YaoJun Zhang; Wei Wei; MinShan Chen; Li Xu; Anna Kan; Ming Shi
Precision Medicine and Imaging
Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Sophia C. Kamran; Yuzhen Zhou; Keisuke Otani; Michael Drumm; Yukako Otani; Shulin Wu; Chin-Lee Wu; Adam S. Feldman; Matthew Wszolek; Richard J. Lee; Philip J. Saylor; Jochen Lennerz; Eliezer Van Allen; Henning Willers; Theodore S. Hong; Yang Liu; Elai Davicioni; Ewan A. Gibb; William U. Shipley; Kent W. Mouw; Jason A. Efstathiou; David T. Miyamoto
Translational Cancer Mechanisms and Therapy
Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
Adrian Marino-Enriquez; Jan Philipp Novotny; Doga C. Gulhan; Isabella Klooster; Antuan V. Tran; Macy Kasbo; Meijun Z. Lundberg; Wen-Bin Ou; Derrick L. Tao; Daniel F. Pilco-Janeta; Victor Y. Mao; Frank T. Zenke; Brittaney A. Leeper; Prafulla C. Gokhale; Glenn S. Cowley; Laurence H. Baker; Karla V. Ballman; David E. Root; Joachim Albers; Peter J. Park; Suzanne George; Jonathan A. Fletcher
Cancer-Associated Fibroblast-Like Tumor Cells Remodel the Ewing Sarcoma Tumor Microenvironment
Emma D. Wrenn; April A. Apfelbaum; Erin R. Rudzinski; Xuemei Deng; Wei Jiang; Sudha Sud; Raelene A. Van Noord; Erika A. Newman; Nicolas M. Garcia; Aya Miyaki; Virginia J. Hoglund; Shruti S. Bhise; Sami B. Kanaan; Olivia G. Waltner; Scott N. Furlan; Elizabeth R. Lawlor
A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells
Veronica Calvo; Wei Zheng; Anna Adam-Artigues; Kirk A. Staschke; Xin Huang; Julie F. Cheung; Ana Rita Nobre; Sho Fujisawa; David Liu; Maria Fumagalli; David Surguladze; Michael E. Stokes; Ari Nowacek; Mark Mulvihill; Eduardo F. Farias; Julio A. Aguirre-Ghiso
Deuterium Magnetic Resonance Imaging Using Deuterated Water-Induced 2H-Tissue Labeling Allows Monitoring Cancer Treatment at Clinical Field Strength
Hirofumi Asano; Abdelazim Elsayed Elhelaly; Fuminori Hyodo; Ryota Iwasaki; Yoshifumi Noda; Hiroki Kato; Koki Ichihashi; Hiroyuki Tomita; Masaharu Murata; Takashi Mori; Masayuki Matsuo
The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
Timothy J. Brown; Arielle Yablonovitch; Jacob E. Till; Jennifer Yen; Lesli A. Kiedrowski; Ryan Hood; Mark H. O'Hara; Ursina Teitelbaum; Thomas B. Karasic; Charles Schneider; Erica L. Carpenter; Katherine Nathanson; Susan M. Domchek; Kim A. Reiss
SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials
Benedetta Conte; Luca Boni; Giancarlo Bisagni; Antonio Durando; Giovanni Sanna; Stefania Gori; Ornella Garrone; Stefano Tamberi; Sabino De Placido; Francesco Schettini; Antonio Pazzola; Riccardo Ponzone; Filippo Montemurro; Gianluigi Lunardi; Rosario Notaro; Maria De Angioletti; Anna Turletti; Mauro Mansutti; Fabio Puglisi; Antonio Frassoldati; Mauro Porpiglia; Alessandra Fabi; Daniele Generali; Giovanni Scognamiglio; Maura Rossi; Fara Brasó-Maristany; Aleix Prat; Barbara Cardinali; Patrizia Piccioli; Martina Serra; Sonia Lastraioli; Claudia Bighin; Francesca Poggio; Matteo Lambertini; Lucia Del Mastro
CD24hiCD27+ Bregs within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer
Huanhuan Huang; Yao Yao; Lesang Shen; Jingxin Jiang; Ting Zhang; Jia Xiong; Jiaxin Li; Shanshan Sun; Siwei Zheng; Fang Jia; Jun Zhou; Xiuyan Yu; Wuzhen Chen; Jun Shen; Wenjie Xia; Xuan Shao; Qingqing Wang; Jian Huang; Chao Ni
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds